AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S. for the treatment of patients with muscle-invasive bladder cancer.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca sBLA for Imfinzi granted Priority Review in MIBC
- AstraZeneca announces FDA approval for Imfinzi
- AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
- AstraZeneca appoints Iskra Reic as Executive Vice President, International
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List